Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial - Concepedia

Concepedia

Publication | Open Access

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial

DOI Full Paper Access

28

Citations

37

References

2022

Year

Richard B. Lipton, Patricia Pozo‐Rosich, Andrew Blumenfeld, Ye Li, Lawrence Severt, Jonathan Stokes, Lela Creutz, Pranav Gandhi, David W. Dodick

Abstract

This study provides Class II evidence that daily atogepant is associated with improvements in health-related quality-of-life measures in patients with 4-14 migraine days per month.

References

	Year	Citations

Page 1